Navigation Links
Tips from the journals of the American Society for Microbiology
Date:12/23/2008

New Alcohol-Based Hand Sanitizer May Minimize Viral Transmission, Including Norovirus

A newly developed ethanol-based hand sanitizer may significantly impact public health by minimizing the transmission of multiple viruses, including norovirus, from food handlers and care providers. The researchers from the University of Ottawa, Ontario, Canada, and North Carolina State University, Raleigh report their findings in the August 2008 issue of the journal Applied and Environmental Microbiology.

The annual number of food-related infections in the U.S. is an estimated 76 million, with norovirus accounting for up to 59% of the viral cases. Contamination of ready-to-eat items by food handlers largely attributes to the high rate of infections, emphasizing the importance of proper hand hygiene. In addition to washing with soap and water some organizations such as the U.S. Centers for Disease Control and Prevention and the World Health Organization recommend the use of alcohol-based hand sanitizers citing such advantages as faster and greater microbial kill, ease of use and time savings, as well as independence from sinks and running water.

In the study the researchers formed a synergistic blend of ethanol, polyquaternium polymer and organic acid and tested its capability to inhibit human and animal viruses. When compared with a benchmark alcohol-based hand sanitizer, results showed higher levels of reduced infectivity of human rotavirus, adenovirus type 5, poliovirus type 1, and norovirus, as well as feline calicivirus and murine norovirus type 1 from the new ethanol-based sanitizer.

"Based on these results, we conclude that this new ethanol-based hand sanitizer is a promising option for reducing the transmission of enteric viruses, including norovirus, by food handlers and care providers," say the researchers.

(D.R. Macinga, S.A. Sattar, L. Jaykus, J.W. Arbogast. 2008. Improved inactivation of nonenveloped enteric viruses and their surrogates by a novel alcohol-based hand sanitizer. Applied and Environmental Microbiology, 74. 16: 5047-5052.)


New Oral Vaccine May Protect Against Bubonic Plague

Researchers from the Institut Pasteur in Paris, France used a less virulent ancestor to the highly infectious bubonic plague to develop a potentially safe, efficient and inexpensive live oral vaccine. They report their findings in the August 2008 issue of the journal Infection and Immunity.

Transmitted by infected fleas, Yersinia pestis is the causative agent responsible for bubonic and pneumonic plague. Both highly contagious, the bubonic form of the disease is the most common in the world and can be treated; however, pneumonic plague is almost always fatal within 3 days of infection. Pneumonic plague can also be generated into aerosols and transmitted from human to human placing it at serious risk for use as weapon of bioterrorism.

Yersinia pseudotuberculosis shares a genetic identity rate of 95% with Y. pestis, but is much less virulent and rarely attributed to disease-related fatalities. In the study 41 strains of Y. pseudotuberculosis were screened for low pathogenicity. Researchers identified one strain (IP32680) which was then tested and found to persist in the mouse intestine for 2 months following intragastric and subcutaneous inoculation without any clinical signs of disease. The previously inoculated mice were then challenged intravenously with Y. pestis following which low levels of the bacteria were found in the organs and blood. Finally, IP32680 was administered orally and results showed that one dose protected 75% of mice, while two doses protected 88%.

"We report that oral inoculation with a Y. pseudotuberculosis strain, selected for its very low virulence, induces an efficient immunity against bubonic plague without causing adverse reactions," say the researchers. "This demonstrates that a live attenuated Y. pseudotuberculosis can be a promising vaccine against bubonic plague."

(T. Blisnick, P. Ave, M. Huerre, E. Carniel, C.E. Demeure. 2008. Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infection and Immunity, 76. 8: 3808-3816.)


Oral Administration of Lactobacillus from Breast Milk May Treat Common Infection in Lactating Mothers

Oral administration of lactobacillus strains found in breast milk may provide an alternative method to antibiotics for effectively treating mastitis, a common infection that occurs in lactating mothers say researchers from Spain. They report their findings in the August 2008 issue of the journal Applied and Environmental Microbiology.

Mastitis, inflammation of one or more lobules of the mammary gland, occurs in anywhere from 3 to 33% of lactating mothers and of those incidences 75 to 95% are diagnosed within the first twelve weeks postpartum. While Staphylococcus aureus and Staphylococcus epidermidis are considered to be the main infectious agents associated with mastitis, increased multi-drug resistance to antibiotics are making such infections difficult to treat, therefore prompting researchers to explore alternative treatment options.

In prior studies researchers collected lactobacillus strains from the breast milk of healthy mothers and found the probiotic potential of Lactobacillus gasseri and Lactobacillus salivarious to be comparable to strains currently used in commercial probiotic products. Here the researchers randomly divided twenty women diagnosed with staphylococcal mastitis into two groups, a probiotic group and a control. The probiotic group received the same daily dosage of L. salivarius and L. gasseri for four weeks, both of which were originally isolated from breast milk. Results showed that on day zero staphylococcal counts in both groups were similar. At day fourteen women in the probiotic group were displaying no clinical signs of mastitis, but infection in the control group persisted. Finally, on day thirty the staphylococcal count was lower in the probiotic group and L. salivarius and L. gasseri were detected in milk samples from six of the ten women.

"In conclusion, L. salivarius CECT5713 and L. gasseri CECT5714 appear to be an efficient alternative for the treatment of lactational infectious mastitis during lactation," say the researchers.

(E. Jimenez, L. Fernandez, A. Maldonado, R. Martin, M. Olivares, J. Xaus, J.M. Rodriguez. 2008. Oral administration of Lactobacillus strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. Applied and Environmental Microbiology, 74. 15: 4650-4655.)


'/>"/>

Contact: Carrie Slijepcevic
cslijepcevic@asmusa.org
American Society for Microbiology
Source:Eurekalert

Related biology technology :

1. Tips from the journals of the American Society for Microbiology
2. Tips from the journals of the American Society for Microbiology
3. Three Expert Opinion Journals now Publishing Original Research
4. ScienceDirect to Host French-Language Journals from Elsevier Masson
5. Tips from the Journals of the American Society for Microbiology
6. Elsevier Introduces The American Journal of Medicine Blog
7. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
8. Transgenomic Receives Accreditation From College of American Pathologists
9. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
10. Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
11. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):